drugset / Trial / NCT06194864
Drug Interaction Study
Phase 1
Completed
45 enrolled
Emalex Biosciences Inc.
Cambridge Cognition Ltd · collabSyneos Health · collab
Non-randomizedParallel-groupOpen-labelBasic science
Summary
This is a single center, 2-Part, Phase 1, open-label, fixed-sequence, drug-drug interaction study designed to compare the PK of ecopipam when administered alone and in combination with itraconazole (Part 1) or rifampicin (Part 2) in healthy subjects.
Timeline
- Start
- 2024-01-18
- Primary completion
- 2024-05-14
- Completion
- 2024-05-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ecopipam | Small molecule | 89.6 mg | — |
| Subject | Ecopipam | Small molecule | 179.2 mg | — |
| Background | Itraconazole | Small molecule | 200 mg | — |
| Background | Rifampin | Small molecule | 600 mg | — |
Indications
No indication recorded.